Nurix Therapeutics (NRIX) Total Liabilities (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Total Liabilities data on file, last reported at $155.2 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $155.2 million, up 15.74% year-over-year; the trailing twelve-month figure through Feb 2026 was $155.2 million (up 15.74% YoY), and the FY2025 annual result was $149.4 million, up 4.94% from the prior year.
• Total Liabilities climbed to $155.2 million in Q1 2026 per NRIX's latest filing, from $149.4 million in the prior quarter.
• Over five years, Total Liabilities peaked at $155.2 million in Q1 2026 and troughed at $74.4 million in Q3 2023.
• A 5-year average of $129.5 million and a median of $136.7 million in 2024 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2023 and 2024: Total Liabilities tumbled 36.32% in 2023, then soared 83.85% in 2024.
• A 5-year view of Total Liabilities shows it stood at $113.1 million in 2022, then jumped by 37.18% to $155.1 million in 2023, then decreased by 8.22% to $142.4 million in 2024, then rose by 4.94% to $149.4 million in 2025, then rose by 3.92% to $155.2 million in 2026.
• Business Quant data shows NRIX's Total Liabilities at $155.2 million in Q1 2026, $149.4 million in Q4 2025, and $150.2 million in Q3 2025.